Clinical Trial Detail

NCT ID NCT03872388
Title Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

triple-receptor negative breast cancer

Therapies

Atorvastatin + Capecitabine

Capecitabine

Age Groups: senior adult

No variant requirements are available.